Table 2.
Radiologic features and Pulmonary function test of ANCA-IIP and IIP
| Characteristic | ANCA-IIP (n = 61) | IIP(n = 286) | P -value |
|---|---|---|---|
| HRCT Abnormalities | |||
| Ground-glass opacity | 55 (90.2) | 209 (73.1) | 0.005 |
| Traction bronchiectasis | 21 (34.4) | 62 (21.7) | 0.034 |
| Honeycombing | 10 (16.4) | 48 (16.8) | 0.941 |
| Reticular pattern | 36 (59.0) | 169 (59.1) | 0.991 |
| Fibrosisa | 22 (36.1) | 72 (25.2) | 0.082 |
| HRCT patterns | |||
| UIP | 9 (14.8) | 41 (14.3) | 0.933 |
| Non-UIP | |||
| NSIP | 36 (59.0) | 112 (39.2) | 0.004 |
| OP | 1 (1.6) | 31 (10.8) | 0.024 |
| NSIP with OP overlap | 0 (0) | 3 (1.0) | 1.000 |
| Unclassifiable | 15 (24.6) | 99 (34.6) | 0.130 |
| Pulmonary function tests | |||
| Baseline FEV1, % predicted | 80.60 (6.10,94.00) | 78.00 (64.40,90.90) | 0.209 |
| Baseline FVC, % predicted | 82.50 (68.30,93.80) | 77.10 (62.30,91.10) | 0.129 |
| Baseline TLC, % predicted | 73.80 (65.80,85.25) | 73.30 (59.20,83.50) | 0.293 |
| Baseline DLCO, % predicted | 60.00 (47.20,69.40) | 56.30 (43.00,70.25) | 0.317 |
| ΔFEV1, % predicted b | −0.61 ± 8.82 | 1.81 ± 10.92 | 0.243 |
| ΔFVC, % predicted b | 0.28 ± 11.01 | 3.87 ± 12.74 | 0.143 |
| ΔTLC, % predicted b | 0.33 ± 10.9 | 1.32 ± 11.34 | 0.675 |
| ΔDLCO, % predicted b | −0.89 ± 11.89 | 1.33 ± 12.99 | 0.390 |
| pulmonary function progression b | 11 (32.3) | 32 (29.3) | 0.740 |
| Pulmonary function stable b | 19 (55.9) | 56 (51.4) | 0.646 |
| Pulmonary function improvement b | 4 (11.8) | 21 (19.3) | 0.315 |
| Treatment | |||
| Corticosteroids | 52 (85.2) | 205 (71.7) | 0.028 |
| Medium dose | 17 (27.9) | 59 (20.6) | 0.191 |
| High dose | 34 (55.7) | 144 (50.3) | 0.445 |
| Cyclophosphamide | 14 (23.0) | 31 (10.8) | 0.011 |
| Other immunosuppressants c | 3 (4.9) | 22 (7.7) | 0.591 |
| Anti-fibrosis d | 6 (9.8) | 36 (12.6) | 0.550 |
| None e | 10 (16.4) | 25 (8.7) | 0.068 |
| Death of all cause | 11 (18.0) | 60 (21.0) | 0.605 |
Data are presented as the medians (IQRs), means ± SDs or No. (%)
ANCA anti-neutrophil cytoplasmic antibody, IIP idiopathic interstitial pneumonia, HRCT high resolution computed tomography, UIP usual interstitial pneumonia, NSIP nonspecific interstitial pneumonia, OP organizing pneumonia, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, TLC total lung capacity, DLCO diffusing capacity of lung for carbon monoxide
aFibrosis was radiologically defined as the presence of honeycombing and traction bronchiectasis; honeycombing and reticular patterns; or traction bronchiectasis and reticular patterns
bANCA-IIP: n = 34; IIP: n = 109
cOther immunosuppressants include tacrolimus, azathioprine, mycophenolate mofetil, methotrexate, hydroxychloroquine, and tripterygium wilfordii
dAnti-fibrosis include nintedanib and pirfenidone
eNone represents not receiving anti-inflammatory and anti-fibrotic therapy